Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 14/20 | 0.76 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719506 | 1.00 | TEAD1 (0.76) | TEAD1TAS2R14DDR1EPHB2DDR2 | |
| SCHEMBL22719832 | 1.00 | TEAD1 (0.76) | TEAD1TAS2R14DDR1EPHB2DDR2 | |
| SCHEMBL22719813 | 0.87 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL29504984 | 0.87 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL22719643 | 0.87 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL22732053 | 0.87 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL29505012 | 0.87 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL22719665 | 0.82 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL22719792 | 0.82 | TEAD1 (1.00) | TEAD1 | |
| SCHEMBL22719790 | 0.82 | TEAD1 (1.00) | TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885TAS2R14 4004/4885DDR1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.